{"id":"NCT02480712","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection","officialTitle":"A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-01","primaryCompletion":"2016-04-29","completion":"2016-06-22","firstPosted":"2015-06-24","resultsPosted":"2017-06-01","lastUpdate":"2018-11-16"},"enrollment":107,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/GS-5816","EpclusaÂ®"]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL 12 Weeks","deltaMin":95.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["28369210"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":56},"commonTop":["Fatigue","Headache","Upper respiratory tract infection","Diarrhoea","Arthralgia"]}}